-
Uddannelse
Find uddannelse
Studievejledning
Kvalitet
- Forskning
-
Samarbejde
Virksomheder
Kommuner og regioner
Gymnasier
Myndigheder
-
Om AU
Organisation
Kontakt
Om AU
- Organisation
- Ledelse
- Strategi
- AU i tal
- AU's historie
- Internationalt samarbejde
- Bæredygtighed
- Campus 2.0
- Diversitet og ligestilling
- Ledige stillinger
- Presse
- Kontakt
Population pharmacokinetics of meropenem in plasma and subcutis from patients on extracorporeal membrane oxygenation treatment
Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923145/pdf/e02390-17.pdf
Forlagets udgivne version
DOI
- https://doi.org/10.1128/AAC.02390-17
Forlagets udgivne version
- Pelle Hanberg
- Kristina Öbrink-Hansen ,
- Anders Thorsted, Uppsala University ,
- Mats Bue
- Mikkel Tøttrup
- Lena E Friberg, Uppsala University ,
- Tore Forsingdal Hardlei
- Kjeld Søballe ,
- Jakob Gjedsted
- Institut for Klinisk Medicin - Ortopædkirurgisk afdeling E, THG
- Institut for Klinisk Medicin - Ortopædkirurgi, Horsens
- Institut for Klinisk Medicin - Bedøvelse
- Institut for Klinisk Medicin - Infektionssygdomme
- Institut for Klinisk Medicin - Ortopædkirurgisk afdeling, Randers
- Institut for Retsmedicin - Retskemisk
- Institut for Klinisk Medicin - Anæstesiologisk afdeling, SKS
The objectives of this study were to describe meropenem pharmacokinetics (PK) in plasma and/or subcutaneous adipose tissue (SCT) in critically ill patients receiving ECMO treatment, and to develop a population PK model to simulate alternative dosing regimens and modes of administration. We conducted a prospective observational study. Ten patients on ECMO treatment received meropenem (1 or 2 g) intravenously over 5 min every 8 hours. Serial SCT concentrations were determined using microdialysis and compared with plasma concentrations. A population PK model of SCT and plasma data was developed using NONMEM. Time above clinical breakpoint MIC forPseudomonas aeruginosa(8 mg/L) was predicted for each patient. The following targets were evaluated: 40%fT>MIC, 100%fT>MIC and 100%fT>4xMIC. For all dosing regimens simulated in both plasma and SCT 40%fT>MIC was attained. However, prolonged meropenem infusion would be needed for 100%fT>MIC and 100%fT>4xMIC to be obtained. Meropenem plasma and SCT concentrations were associated with estimated creatinine-clearance (eCLCr). Simulations showed that in patients with increased eCLCr, dose increment or continuous infusion may be needed to obtain therapeutic meropenem concentrations. In conclusion, our results show that when using traditional targets of 40%fT>MIC standard meropenem dosing of 1 g intravenously 8-hourly is likely to provide sufficient meropenem concentration to treat the problematic pathogenP. aeruginosafor patients receiving ECMO treatment. However, for patients with an increased eCLCror if more aggressive targets like 100%fT>MIC or 100%fT>4xMIC are adopted, dose increment or continuous infusion may be needed.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | e02390-17 |
| Tidsskrift | Antimicrobial Agents and Chemotherapy |
| Vol/bind | 62 |
| Nummer | 5 |
| Antal sider | 13 |
| ISSN | 0066-4804 |
| DOI | |
| Status | Udgivet - maj 2018 |
Se relationer på Aarhus Universitet Citationsformater
ID: 125736536